thiazolidin-4-one derivatives 4a-c and 8a-e were designed and prepared. All the synthesized compounds were evaluated for their in vitro COX-2 selectivity and anti-inflammatory activity in vivo. Compounds 8c and 8d showed the best overall in vitro COX-2 selectivity (selectivity indexes of 4.56 and 5.68 respectively) and in vivo activities (edema inhibition %=61.8 and 67 after 3h, respectively) in comparison
设计并制备了两个系列的新的
噻唑烷-4-酮衍
生物4a-c和8a-e。评价所有合成的化合物的体外COX-2选择性和体内抗炎活性。与参考药物
塞来昔布(SI = 7.29,3小时后
水肿抑制%= 60)。此外,还评估了8c和8d的平均有效抗炎剂量(分别为ED50 = 27.7和18.1μmol/ kg,
塞来昔布ED50 = 28.2μmol/ kg)和致溃疡性(致溃疡性潜力相对于celecoxib降低85%,92) % 分别。